Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT05652894	TitleA Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer	Fase Fase 3	Date Added 2022-12-15	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Aún no se ha contratado	Drogas HX008, Investigator's Choice Chemotherapy	Etiquetas MSI-H/ MMRd
NCT ID NCT05672316	TitleBotensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy	Fase Fase 1	Date Added 2023-01-05	Ubicación California, United States	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Balstilimab, Botensilimab, Regorafenib	Etiquetas MSS/ MMRp
NCT ID NCT05673148	TitlePrueba de la adición de la terapia ablativa total al tratamiento sistémico habitual para el cáncer colorrectal metastásico limitado, el estudio ERASur	Fase Fase 3	Date Added 2023-01-06	Ubicación Arizona, United States California, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Iowa, United States Kentucky, United States Maryland, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Dakota, United States Ohio, United States Oklahoma, United States Pennsylvania, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Washington, United States Wisconsin, United States	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Quimioterapia	Etiquetas MSS/ MMRp
NCT ID NCT05677113	TitleA Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver	Fase Fase 2	Date Added 2023-01-10	Ubicación Canadá	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Placebo, QBECO	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05676190	TitleClinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer	Fase No aplicable	Date Added 2023-01-09	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05608044	TitleA Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases	Fase Fase 2	Date Added 2022-11-08	Ubicación Arizona, United States California, United States Colorado, United States Delaware, United States Florida, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Rhode Island, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Bélgica Brasil Francia Georgia Italia Russian Federation España	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Balstilimab, Botensilimab, Regorafenib, TAS-102	Etiquetas MSS/ MMRp
NCT ID NCT05609370	TitleA Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer	Fase Phase 1, Phase 2	Date Added 2022-11-08	Ubicación Alaska, United States Arizona, United States California, United States Florida, United States Indiana, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nevada, United States New Mexico, United States New York, United States North Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Australia China Puerto Rico	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Bevacizumab, capecitabine, LBL-007, Tislelizumab	Etiquetas MSS/ MMRp
NCT ID NCT05425940	TitleStudy of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303)	Fase Fase 3	Date Added 2022-06-21	Ubicación Alabama, United States Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nebraska, United States New Mexico, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Virginia, United States Washington, United States Australia Bélgica Francia Alemania Hong Kong Hungary Corea, República de Nueva Zelanda Polonia Portugal Singapur España Taiwán Tailandia Reino Unido	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Regorafenib, XL092, Stivarga, Tecentriq	Etiquetas MSS/ MMRp
NCT ID NCT05627635	TitleFOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer	Fase Phase 1, Phase 2	Date Added 2022-11-25	Ubicación California, United States	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Balstilimab, Botensilimab, fluorouracil, Leucovorin Calcium, oxaliplatin	Etiquetas MSS/ MMRp
NCT ID NCT05328908	TitleUn estudio de combinación de dosis fija de nivolumab-relatlimab frente a regorafenib o TAS-102 en participantes con cáncer colorrectal metastásico de última línea	Fase Fase 3	Date Added 2022-04-14	Ubicación Arkansas, United States California, United States Connecticut, United States Florida, United States Georgia, United States Idaho, United States Indiana, United States Massachusetts, United States Michigan, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Virginia, United States Wisconsin, United States Argentina Australia Austria Bélgica Canadá Chile China Czechia Francia Alemania Italia Japón Corea, República de Países Bajos Polonia Puerto Rico Singapur España Suecia Suiza Taiwán	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Nivolumab-relatlimab FDC, Regorafenib, TAS-102, Lonsurf, Opdivo, Stivarga	Etiquetas MSS/ MMRp

Showing 271 to 280 of 299 entries